Identification of genotype 2 HCV in serotype-1 hepatitis C patients unresponsive to daclatasvir plus asunaprevir treatment

Jun Inoue, Atsushi Kanno, Yuta Wakui, Masahito Miura, Tomoo Kobayashi, Tatsuki Morosawa, Takayuki Kogure, Eiji Kakazu, Masashi Ninomiya, Yasuyuki Fujisaka, Teruyuki Umetsu, Satoshi Takai, Takuya Nakamura, Tooru Shimosegawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

It is important to determine the genotypes or serotypes of hepatitis C virus (HCV) in patients before treatment with direct-acting antiviral agents (DAAs), because the effects of DAAs differ among genotypes. In Japan, two tests for HCV typing are available clinically, but only serotyping, not genotyping, is approved by the public health insurance. Although most serotype-1 Japanese patients are infected with genotype 1b HCV, it is known that a small proportion of patients show different results from two typing methods. This study focused on such patients and the effectiveness of treatment with daclatasvir plus asunaprevir (DCV/ASV) was evaluated. We analyzed 644 DCV/ASV-treated patients with serotype 1 or genotype 1b, and among them, 166 serotype-1 patients received a commercial-based direct sequencing (DS) test for resistant-associated variants of genotype 1b HCV. We found four patients (2.4%) with DS test failure, suggesting that the PCR primers targeting genotype 1b may not match. Importantly, none of the four patients achieved a sustained virological response. Our in-house DS test analyzing the 5′-untranslated region and coding regions for NS4 and NS5B of HCV showed that three of the four patients were infected with genotype 2 HCV, and one patient was infected with genotype 1a HCV. No recombinant virus of different genotypes was found. This study indicates that a subset of serotype-1 hepatitis C patients is infected with HCV of genotype 2 or 1a in Japan and that DCV/ASV is not effective for such patients. Thus, attention should be paid to DAA treatment without HCV genotyping.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalTohoku Journal of Experimental Medicine
Volume241
Issue number1
DOIs
Publication statusPublished - 2017 Jan

Keywords

  • Asunaprevir
  • Daclatasvir
  • Genotype
  • HCV
  • Serotype

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Identification of genotype 2 HCV in serotype-1 hepatitis C patients unresponsive to daclatasvir plus asunaprevir treatment'. Together they form a unique fingerprint.

  • Cite this

    Inoue, J., Kanno, A., Wakui, Y., Miura, M., Kobayashi, T., Morosawa, T., Kogure, T., Kakazu, E., Ninomiya, M., Fujisaka, Y., Umetsu, T., Takai, S., Nakamura, T., & Shimosegawa, T. (2017). Identification of genotype 2 HCV in serotype-1 hepatitis C patients unresponsive to daclatasvir plus asunaprevir treatment. Tohoku Journal of Experimental Medicine, 241(1), 21-28. https://doi.org/10.1620/tjem.241.21